In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Loxo Oncology goes public, nets $71.4mm

Executive Summary

Loxo Oncology Inc. (cancer therapeutics firm launched last year by Aisling Capital) netted $71.4mm in its initial public offering of 5.9mm common shares (including partial exercise of the overallotment) at $13. The company filed in June, and in mid-July announced that it planned to sell 4.4mm shares for between $12-14.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies